- 著者
- Akihiko Nogami Takashi Kurita Haruhiko Abe Kenji Ando Toshiyuki Ishikawa Katsuhiko Imai Akihiko Usui Kaoru Okishige Kengo Kusano Koichiro Kumagai Masahiko Goya Yoshinori Kobayashi Akihiko Shimizu Wataru Shimizu Morio Shoda Naokata Sumitomo Yoshihiro Seo Atsushi Takahashi Hiroshi Tada Shigeto Naito Yuji Nakazato Takashi Nishimura Takashi Nitta Shinichi Niwano Nobuhisa Hagiwara Yuji Murakawa Teiichi Yamane Takeshi Aiba Koichi Inoue Yuki Iwasaki Yasuya Inden Kikuya Uno Michio Ogano Masaomi Kimura Shun-ichiro Sakamoto Shingo Sasaki Kazuhiro Satomi Tsuyoshi Shiga Tsugutoshi Suzuki Yukio Sekiguchi Kyoko Soejima Masahiko Takagi Masaomi Chinushi Nobuhiro Nishi Takashi Noda Hitoshi Hachiya Masataka Mitsuno Takeshi Mitsuhashi Yasushi Miyauchi Aya Miyazaki Tomoshige Morimoto Hiro Yamasaki Yoshifusa Aizawa Tohru Ohe Takeshi Kimura Kazuo Tanemoto Hiroyuki Tsutsui Hideo Mitamura on behalf of the JCS/JHRS Joint Working Group
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-20-0637, (Released:2021-06-01)
- 参考文献数
- 1350
- 被引用文献数
- 75
- 著者
- Yurika Iwasawa Naoto Hosokawa Mariko Harada Satoshi Hayano Akihiko Shimizu Daisuke Suzuki Kei Nakashima Makito Yaegashi
- 出版者
- The Japanese Society of Internal Medicine
- 雑誌
- Internal Medicine (ISSN:09182918)
- 巻号頁・発行日
- pp.0787-18, (Released:2018-09-12)
- 参考文献数
- 20
- 被引用文献数
- 8
A 62-year-old man with diabetes mellitus and a two-day history of fever and dyspnea presented at our hospital. He was diagnosed with community-acquired pneumonia (CAP), septic shock, and respiratory failure. Sputum Gram staining revealed Gram-negative coccobacilli. Based on the Gram staining findings and history, Acinetobacter baumannii was considered as one of the causative organisms of his CAP. Consequently, he was successfully treated with the initial administration of meropenem. We suggest that A. baumannii should be considered as one of the possible causative organisms of CAP based on a fulminant clinical course, and the presence of Gram-negative coccobacilli.
- 著者
- Tomoyuki Kabutoya Takeshi Mitsuhashi Akihiko Shimizu Takashi Nitta Hideo Mitamura Takashi Kurita Haruhiko Abe Yuji Nakazato Naokata Sumitomo Kazushige Kadota Kazuo Kimura Ken Okumura
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Reports (ISSN:24340790)
- 巻号頁・発行日
- vol.3, no.2, pp.69-76, 2021-02-10 (Released:2021-02-10)
- 参考文献数
- 25
- 被引用文献数
- 1
Background:There has been no large multicenter clinical trial on the prognosis of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) in Japanese patients with coronary artery disease (CAD). The aim of the present study was to compare differences in the prognoses of Japanese patients with CAD between primary and secondary prevention, and to identify potential predictors of prognosis.Methods and Results:We investigated 392 CAD patients (median age 69 years, 90% male) treated with ICD/CRT-D enrolled in the Japan Implantable Devices in CAD (JID-CAD) Registry. The primary endpoint was all-cause death, and the secondary endpoint was appropriate ICD therapies. Endpoints were assessed by dividing patients into primary prevention (n=165) and secondary prevention (n=227) groups. The mean (±SD) follow-up period was 2.1±0.9 years. The primary endpoint was similar in the 2 groups (P=0.350).Conclusions:The mortality rate in Japanese patients with CAD who underwent ICD/CRT-D implantation as primary prevention was not lower than that of patients who underwent ICD/CRT-D implantation as secondary prevention, despite the lower cardiac function in the patients undergoing ICD/CRT-D implantation as primary prevention.
- 著者
- Akihiko Shimizu
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- vol.78, no.12, pp.2851-2853, 2014-11-25 (Released:2014-11-25)
- 参考文献数
- 13
- 被引用文献数
- 3 3
- 著者
- Hiroshi Inoue Ken Okumura Hirotsugu Atarashi Takeshi Yamashita Hideki Origasa Naoko Kumagai Masayuki Sakurai Yuichiro Kawamura Isao Kubota Kazuo Matsumoto Yoshiaki Kaneko Satoshi Ogawa Yoshifusa Aizawa Masaomi Chinushi Itsuo Kodama Eiichi Watanabe Yukihiro Koretsune Yuji Okuyama Akihiko Shimizu Osamu Igawa Shigenobu Bando Masahiko Fukatani Tetsunori Saikawa Akiko Chishaki on behalf of the J-RHYTHM Registry Investigators
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-13-0290, (Released:2013-05-25)
- 参考文献数
- 24
- 被引用文献数
- 52 110
Background: Target anticoagulation levels for warfarin in Japanese patients with non-valvular atrial fibrillation (NVAF) are unclear. Methods and Results: Of 7,527 patients with NVAF, 1,002 did not receive warfarin (non-warfarin group), and the remaining patients receiving warfarin were divided into 5 groups based on their baseline international normalized ratio (INR) of prothrombin time (≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0). Patients were followed-up prospectively for 2 years. Primary endpoints were thromboembolic events (cerebral infarction, transient ischemic attack, and systemic embolism), and major hemorrhage requiring hospital admission. During the follow-up period, thromboembolic events occurred in 3.0% of non-warfarin group, but at lower frequencies in the warfarin groups (2.0, 1.3, 1.5, 0.6, and 1.8%/2 years for INR values of ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0059). Major hemorrhage occurred more frequently in warfarin groups (1.5, 1.8, 2.4, 3.3, and 4.1% for INR values ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0041) than in non-warfarin group (0.8%/2 years). These trends were maintained when the analyses were confined to patients aged ≥70 years. Conclusions: An INR of 1.6–2.6 is safe and effective at preventing thromboembolic events in patients with NVAF, particularly patients aged ≥70 years. An INR of 2.6–2.99 is also effective, but associated with a slightly increased risk in major hemorrhage. (UMIN Clinical Trials Registry UMIN000001569)